1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
• 1.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 First-Line Anti-TB Drugs

1.2.3 Second-Line Anti-TB Drugs

1.2.4 Others

1.3 Market by Application

1.3.1 Global Drug-Resistant Tuberculosis Treatment Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Hospital Pharmacy

1.3.3 Online Pharmacy

1.3.4 Retail Pharmacy

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Drug-Resistant Tuberculosis Treatment Market Perspective (2017-2028)
• 2.2 Drug-Resistant Tuberculosis Treatment Growth Trends by Region
• 2.2.1 Drug-Resistant Tuberculosis Treatment Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Drug-Resistant Tuberculosis Treatment Historic Market Size by Region (2017-2022)

2.2.3 Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2023-2028)

2.3 Drug-Resistant Tuberculosis Treatment Market Dynamics

2.3.1 Drug-Resistant Tuberculosis Treatment Industry Trends

2.3.2 Drug-Resistant Tuberculosis Treatment Market Drivers

2.3.3 Drug-Resistant Tuberculosis Treatment Market Challenges

2.3.4 Drug-Resistant Tuberculosis Treatment Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue
• 3.1.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue (2017-2022)

3.1.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Players (2017-2022)

3.2 Global Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Drug-Resistant Tuberculosis Treatment Revenue

3.4 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio

3.4.1 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Drug-Resistant Tuberculosis Treatment Revenue in 2021

3.5 Drug-Resistant Tuberculosis Treatment Key Players Head office and Area Served

3.6 Key Players Drug-Resistant Tuberculosis Treatment Product Solution and Service

3.7 Date of Enter into Drug-Resistant Tuberculosis Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Drug-Resistant Tuberculosis Treatment Breakdown Data by Type

• 4.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Type (2017-2022)
• 4.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2023-2028)

5 Drug-Resistant Tuberculosis Treatment Breakdown Data by Application

• 5.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Application (2017-2022)
• 5.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Drug-Resistant Tuberculosis Treatment Market Size (2017-2028)
• 6.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2017-2022)
• 6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2023-2028)
• 6.4 United States
• 6.5 Canada

7 Europe

• 7.1 Europe Drug-Resistant Tuberculosis Treatment Market Size (2017-2028)
• 7.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2017-2022)
• 7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2023-2028)
• 7.4 Germany
• 7.5 France
• 7.6 U.K.
• 7.7 Italy
• 7.8 Russia
• 7.9 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size (2017-2028)
• 8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Country (2017-2022)
• 8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Country (2023-2028)
• 8.4 China
• 8.5 Japan
• 8.6 South Korea
• 8.7 Southeast Asia
• 8.8 India
• 8.9 Australia

9 Latin America

• 9.1 Latin America Drug-Resistant Tuberculosis Treatment Market Size (2017-2028)
• 9.2 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2017-2022)
• 9.3 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2023-2028)
• 9.4 Mexico
• 9.5 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size (2017-2028)
• 10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2017-2022)
• 10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2023-2028)
• 10.4 Turkey
• 10.5 Saudi Arabia
• 10.6 UAE

11 Key Players Profiles

• 11.1 Sanofi
• 11.1.1 Sanofi Company Detail

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Introduction

11.1.4 Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.1.5 Sanofi Recent Development

11.2 Novartis AG

11.2.1 Novartis AG Company Detail

11.2.2 Novartis AG Business Overview

11.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Introduction

11.2.4 Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.2.5 Novartis AG Recent Development

11.3 Endo International plc

11.3.1 Endo International plc Company Detail

11.3.2 Endo International plc Business Overview

11.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Introduction

11.3.4 Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.3.5 Endo International plc Recent Development

11.4 CMP Pharma

11.4.1 CMP Pharma Company Detail

11.4.2 CMP Pharma Business Overview

11.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Introduction

11.4.4 CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.4.5 CMP Pharma Recent Development

11.5 STI Pharma LLC

11.5.1 STI Pharma LLC Company Detail

11.5.2 STI Pharma LLC Business Overview

11.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Introduction

11.5.4 STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.5.5 STI Pharma LLC Recent Development

11.6 Akorn Incorporated

11.6.1 Akorn Incorporated Company Detail

11.6.2 Akorn Incorporated Business Overview

11.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Introduction

11.6.4 Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.6.5 Akorn Incorporated Recent Development

11.7 Lupin

11.7.1 Lupin Company Detail

11.7.2 Lupin Business Overview

11.7.3 Lupin Drug-Resistant Tuberculosis Treatment Introduction

11.7.4 Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.7.5 Lupin Recent Development

11.8 Johnson & Johnson Services Inc.

11.8.1 Johnson & Johnson Services Inc. Company Detail

11.8.2 Johnson & Johnson Services Inc. Business Overview

11.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Introduction

11.8.4 Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.8.5 Johnson & Johnson Services Inc. Recent Development

11.9 Macleods Pharmaceuticals Ltd

11.9.1 Macleods Pharmaceuticals Ltd Company Detail

11.9.2 Macleods Pharmaceuticals Ltd Business Overview

11.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Introduction

11.9.4 Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.9.5 Macleods Pharmaceuticals Ltd Recent Development

11.10 Pfizer Inc

11.10.1 Pfizer Inc Company Detail

11.10.2 Pfizer Inc Business Overview

11.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Introduction

11.10.4 Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.10.5 Pfizer Inc Recent Development

11.11 Hikma Pharmaceuticals PLC

11.11.1 Hikma Pharmaceuticals PLC Company Detail

11.11.2 Hikma Pharmaceuticals PLC Business Overview

11.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Introduction

11.11.4 Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.11.5 Hikma Pharmaceuticals PLC Recent Development

11.12 Lannett

11.12.1 Lannett Company Detail

11.12.2 Lannett Business Overview

11.12.3 Lannett Drug-Resistant Tuberculosis Treatment Introduction

11.12.4 Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.12.5 Lannett Recent Development

11.13 Mylan N.V.

11.13.1 Mylan N.V. Company Detail

11.13.2 Mylan N.V. Business Overview

11.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Introduction

11.13.4 Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.13.5 Mylan N.V. Recent Development

11.14 Teva Pharmaceutical Industries Ltd

11.14.1 Teva Pharmaceutical Industries Ltd Company Detail

11.14.2 Teva Pharmaceutical Industries Ltd Business Overview

11.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Introduction

11.14.4 Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.14.5 Teva Pharmaceutical Industries Ltd Recent Development

11.15 Fresenius Kabi AG

11.15.1 Fresenius Kabi AG Company Detail

11.15.2 Fresenius Kabi AG Business Overview

11.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Introduction

11.15.4 Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2017-2022)

11.15.5 Fresenius Kabi AG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
• 13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

Industry Insights
The global Drug-Resistant Tuberculosis Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, First-Line Anti-TB Drugs accounting for % of the Drug-Resistant Tuberculosis Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.

China Drug-Resistant Tuberculosis Treatment market size is valued at US$ million in 2021, while the North America and Europe Drug-Resistant Tuberculosis Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Drug-Resistant Tuberculosis Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drug-Resistant Tuberculosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drug-Resistant Tuberculosis Treatment market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drug-Resistant Tuberculosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drug-Resistant Tuberculosis Treatment market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Drug-Resistant Tuberculosis Treatment market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Drug-Resistant Tuberculosis Treatment Breakdown Data by Type

First-Line Anti-TB Drugs

Second-Line Anti-TB Drugs

Others

Drug-Resistant Tuberculosis Treatment Breakdown Data by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Sanofi

Novartis AG

Endo International plc

CMP Pharma

STI Pharma LLC

Akorn Incorporated

Lupin

Johnson & Johnson Services Inc.

Macleods Pharmaceuticals Ltd

Pfizer Inc

Hikma Pharmaceuticals PLC

Lannett

Mylan N.V.

Teva Pharmaceutical Industries Ltd

Fresenius Kabi AG

Frequently Asked Questions

What factors will challenge the Drug-Resistant Tuberculosis Treatment market growth?

Which end-use segment will expand at the fastest CAGR in the Drug-Resistant Tuberculosis Treatment market?

Which are the emerging players in the Drug-Resistant Tuberculosis Treatment market?

How concentrated is the Drug-Resistant Tuberculosis Treatment market?

Which factors are positively contributing to the Drug-Resistant Tuberculosis Treatment market growth?

Which are the novel product innovations in the Drug-Resistant Tuberculosis Treatment market?

Which product segment will emerge as the most lucrative in the Drug-Resistant Tuberculosis Treatment market?

Which factors are increasing the competition in the Drug-Resistant Tuberculosis Treatment market?

Which are the strategic measures taken by the Drug-Resistant Tuberculosis Treatment industry players?

Which region will witness inactive growth during the forecast period?

What key trends are likely to emerge in the Drug-Resistant Tuberculosis Treatment market in the coming years?